The World Health Organization (WHO) has made new recommendations for the usage of two monoclonal antibodies to treat the Ebola virus in its first published guideline.

mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb) are the two monoclonal antibody treatments recommended by the WHO.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The health agency urged the global community to boost access to these lifesaving therapies.

This development follows a systematic assessment and meta-analysis of randomised clinical trials of therapies for the disease.

These trials were carried out during Ebola outbreaks, with the largest of them being conducted in the Democratic Republic of the Congo.

The guidelines will back health care providers caring for Ebola patients, as well as policymakers linked to readiness and response to the disease outbreak. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The guidance also complements clinical care recommendations that outline the optimal supportive care patients with Ebola should get for better recovery.

The two recommended antibody therapies can be used for all Ebola patients, including pregnant and breastfeeding women, children, elderly individuals, and newborns of mothers with Ebola within the initial seven days following birth. 

Guideline Development Group of WHO-selected experts co-chair Dr Richard Kojan said: “This therapeutic guide is a critical tool to fight Ebola. 

“It will help reassure the communities, healthcare workers and patients that this life-threatening disease can be treated, thanks to effective drugs. 

“From now on, people infected with the Ebola virus will have a greater chance of recovering if they seek care as early as possible.”

The WHO also advised against the use of some therapeutics for treating Ebola patients, including ZMapp and remdesivir.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact